Pauline Waight
Research Subjects
Research Interests
Pauline Waight has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Michiel Adrianus Josephus van de Sande
Department of Global Public Health & Bioethics, Julius Center, University Medical Center Utrecht, the Netherlands
3 shared publications - Ebrima Touray
MRC Laboratories Gambia, PO Box 273, Banjul, Gambia
2 shared publications - Katie L. Flanagan
MRC Laboratories Gambia, PO Box 273, Banjul, Gambia
2 shared publications - Melba S Palmero
MRC Laboratories Gambia, PO Box 273, Banjul, Gambia
2 shared publications - Olubukola Ojuola
Department of Pediatrics, Bronx Lebanon Hospital Center, 1650 Selwyn Avenue, Bronx, New York, USA
2 shared publications - Sarah R. Crozier
MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
2 shared publications
Latest Publications
- Open Access
- 14 January 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 6
Placental malaria is associated with attenuated CD4 T-cell responses to tuberculin PPD 12 months after BCG vaccination
Background: Placental malaria (PM) is associated with prenatal malaise, but many PM+ infants are born without symptoms. As malaria has powerful immunomodulatory effects, we tested the hypothesis that PM predicts reduced T-cell responses to vaccine challenge.Methods: We recruited healthy PM+ and PM- infants at birth. At six and 12 months, we stimulated PBMCs with tuberculin purified protein derivative (PPD) and compared expression of CD154, IL-2 and IFNγ by CD4 T-cells to a negative control using flow cytometry.We measured the length, weight and head circumference at birth and 12 months.Results: IL-2 and CD154 expression were low in both groups at both timepoints, without discernable differences. Expression of IFNγ was similarly low at 6 months but by 12 months, the median response was higher in PM- than PM + infants (p= 0.026). The PM+ infants also had a lower weight (p= 0.032) and head circumference (p= 0.041) at 12 months, indicating lower growth rates.At birth, the size and weight of the PM+ and PM- infants were equivalent. By 12 months, the PM+ infants had a lower weight and head circumference than the PM- infants.Conclusions: Placental malaria was associated with reduced immune responses 12 months after immune challenge in infants apparently healthy at birth.
- 14 January 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 6
Open AccessPlacental malaria is associated with attenuated CD4 T-cell responses to tuberculin PPD 12 months after BCG vaccination
Background: Placental malaria (PM) is associated with prenatal malaise, but many PM+ infants are born without symptoms. As malaria has powerful immunomodulatory effects, we tested the hypothesis that PM predicts reduced T-cell responses to vaccine challenge.Methods: We recruited healthy PM+ and PM- infants at birth. At six and 12 months, we stimulated PBMCs with tuberculin purified protein derivative (PPD) and compared expression of CD154, IL-2 and IFNγ by CD4 T-cells to a negative control using flow cytometry.We measured the length, weight and head circumference at birth and 12 months.Results: IL-2 and CD154 expression were low in both groups at both timepoints, without discernable differences. Expression of IFNγ was similarly low at 6 months but by 12 months, the median response was higher in PM- than PM + infants (p= 0.026). The PM+ infants also had a lower weight (p= 0.032) and head circumference (p= 0.041) at 12 months, indicating lower growth rates.At birth, the size and weight of the PM+ and PM- infants were equivalent. By 12 months, the PM+ infants had a lower weight and head circumference than the PM- infants.Conclusions: Placental malaria was associated with reduced immune responses 12 months after immune challenge in infants apparently healthy at birth.
- Open Access
- 14 January 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 16
Placental Malaria is associated with reduced early life weight development of affected children independent of low birth weight
Infection with Plasmodium falciparum during pregnancy contributes substantially to the disease burden in both mothers and offspring. Placental malaria may lead to intrauterine growth restriction or preterm delivery resulting in low birth weight (LBW), which, in general, is associated with increased infant morbidity and mortality. However, little is known about the possible direct impact of the specific disease processes occurring in PM on longer term outcomes such as subsequent retarded growth development independent of LBW.
- 14 January 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 16
Open AccessPlacental Malaria is associated with reduced early life weight development of affected children independent of low birth weight
Infection with Plasmodium falciparum during pregnancy contributes substantially to the disease burden in both mothers and offspring. Placental malaria may lead to intrauterine growth restriction or preterm delivery resulting in low birth weight (LBW), which, in general, is associated with increased infant morbidity and mortality. However, little is known about the possible direct impact of the specific disease processes occurring in PM on longer term outcomes such as subsequent retarded growth development independent of LBW.
- Open Access
- 4 April 2006
- Published by Springer Nature in Virology Journal
- Vol. 3 (1) , 23
Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia
Background/Aim: The study aimed at developing a real-time quantitative PCR assay to monitor HBV serum virus load of chronic carriers enrolled in therapeutic trials. Method: Quantitative real-time PCR assay was carried out using SYBR-Green signal detection and primers specific to the S gene. Thermal cycling was performed in an ABi 5700 sequence detection system. The assay was calibrated against an international HBV DNA standard and inter- and intra-assay reproducibility determined. Levels of viral load were monitored for 1-year in lamivudine treated carriers. Correlation between HBV DNA levels and HBeAg sero-status was determined in untreated carriers. Results: The qPCR assay showed good intra- and inter-assay reproducibility over a wide dynamic range (1.5 × 103 to 1.5 × 108 copies/mL) and correlated well with those from a commercial assay (r = 0.91, (p < 0.001). Viral load levels dropped dramatically but temporarily during and after a short course of lamivudine therapy. HBV DNA was a more reliable indicator of the presence of virus than HBe antigen and was detected in 77.0% (161/209) of HBeAg negative and in all HBeAg positive carriers. Conclusion: This method is reliable, accurate, and reproducible. HBV DNA Quantification by qPCR can be used to monitor the efficacy of HBV therapy and useful in understanding the natural history of HBV in an endemic area.
- 4 April 2006
- Published by Springer Nature in Virology Journal
- Vol. 3 (1) , 23
Open AccessApplication of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia
Background/Aim: The study aimed at developing a real-time quantitative PCR assay to monitor HBV serum virus load of chronic carriers enrolled in therapeutic trials. Method: Quantitative real-time PCR assay was carried out using SYBR-Green signal detection and primers specific to the S gene. Thermal cycling was performed in an ABi 5700 sequence detection system. The assay was calibrated against an international HBV DNA standard and inter- and intra-assay reproducibility determined. Levels of viral load were monitored for 1-year in lamivudine treated carriers. Correlation between HBV DNA levels and HBeAg sero-status was determined in untreated carriers. Results: The qPCR assay showed good intra- and inter-assay reproducibility over a wide dynamic range (1.5 × 103 to 1.5 × 108 copies/mL) and correlated well with those from a commercial assay (r = 0.91, (p < 0.001). Viral load levels dropped dramatically but temporarily during and after a short course of lamivudine therapy. HBV DNA was a more reliable indicator of the presence of virus than HBe antigen and was detected in 77.0% (161/209) of HBeAg negative and in all HBeAg positive carriers. Conclusion: This method is reliable, accurate, and reproducible. HBV DNA Quantification by qPCR can be used to monitor the efficacy of HBV therapy and useful in understanding the natural history of HBV in an endemic area.